The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...
The following is a summary of “Identification and experimental validation of a sialylation–related long noncoding RNA ...
Event-free survival rates at 12 months were 67.8% ... This trial suggests a new treatment option for patients with muscle-invasive bladder cancer; future work should evaluate the relative efficacy ...
Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory ...
Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients ...
Hosted on MSN3d
Drugmaker Pulls Trodelvy's Bladder Cancer ApprovalSacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...
News Medical on MSN3d
New combination treatment authorized for unresectable urothelial cancer patientsAstellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in ...
Parade on MSN6d
This Is One of the Most Common Signs of Bladder Cancer, According to a UrogynecologistDr. Kobashi says that the most common symptom of bladder cancer is blood in urine. The blood can range from bright red to a ...
MedPage Today on MSN3d
Diet and Prostate Cancer; TTFields OK'd for NSCLC; Cancer Studies RetractedThe FDA approved a wearable tumor-treating fields (TTFields) device (Optune Lua) for concurrent use with a PD-1/PD-L1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback